Similarly to last year, this unique forum delved into the complex interplay between Antiphospholipid Syndrome and the coagulation system, spotlighting cutting-edge diagnostics, innovative therapies, and emerging research trends.
The day began with a powerful patient testimony from Nusaiba Masnurah, who shared her journey to “New Normality” after surviving three pulmonary embolisms, discussing her personal challenges and underscoring the critical need for awareness, support, and education.
The scientific program then unfolded with four insights from renowned experts:
- Pier Luigi Meroni shared the latest updates on APS classification criteria, emphasizing the evolving understanding of the disease and explaining how changing definitions may influence clinical practice.
- Bringing innovation to diagnostics, Dr. Lieve Van Hovels introduced Likelihood Ratio-based interpretation for APS antibody tests, a true game-changer for accuracy and harmonization.
- Prof. Katarzyna Fischer then explored established and emerging biomarkers, discussing extended antibody profiles and the role of non-criteria antibodies in complex cases.
- Finally, addressing APS patients with low-risk aPL profiles, Prof. Savino Sciascia presented evidence supporting safe discontinuation of anticoagulation after confirmed aPL negativization.
With nearly 400 participants filling the room, our Joint Session sparked lively discussions, thought-provoking questions, and enthusiastic applause. By bridging research and clinical practice, this moment aimed to advance understanding and optimize APS management, ultimately improving patient outcomes.
EEMEA Hemostasis and AID Team